Présentation de l'entreprise
Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of novel immunotherapies designed for the treatment of cancer. The company functions within the Healthcare sector, specifically in the Biotechnology industry, which implies a focus on high-risk, high-reward research and development cycles aimed at bringing new therapeutic modalities to market. The enterprise maintains a market capitalization of $8.84M, generates annual revenue of $7.70M, and employs a workforce of 23 individuals. These financial metrics indicate a company that is still in a very early stage of commercialization, where the market cap significantly exceeds current revenue, a common characteristic for clinical-stage firms that rely on future product approvals and sales to realize substantial value rather than current profitability.
Santé financière
The company reported revenue of $7.70M over the trailing twelve months, while posting a net income of $-33,376,000 and an EBITDA of $-33,342,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure dominated by research, development, and operational expenses that far exceed current sales, a typical pattern for biotechnology firms in clinical trials. Free cash flow stands at $-24,904,624, indicating that the company is burning cash to fund its pipeline rather than generating liquidity from operations, which limits its immediate financial flexibility without external capital infusion. An analysis of the three key margins shows a gross margin of -270.8%, an operating margin of -224.2%, and a profit margin of 0.0%, all of which indicate that the company is not yet generating profit on its sales and is operating at a loss across all operational levels. In terms of leverage, the company holds $27.50M in cash against $22.96M in debt, with a debt-to-equity ratio of 86.62, suggesting a balance sheet that relies heavily on equity financing rather than debt, though the high debt-to-equity figure signals significant leverage relative to shareholder equity. The current ratio is 3.59, which indicates a strong position in short-term liquidity, as the company possesses more than three times the current assets necessary to cover its short-term liabilities. Furthermore, the Return on Equity is -79.7% and the Return on Assets is -27.7%, metrics that reveal that management has not yet been effective in generating returns on the capital deployed, reflecting the inherent nature of investing in early-stage clinical development before product commercialization.
Évaluation de la valorisation
The trailing P/E ratio is N/A, while the forward P/E is -0.19, and the difference between these figures implies that expected earnings trajectories are currently non-existent due to the company's ongoing losses, rendering traditional earnings-based valuation models inapplicable. The price-to-book ratio is 0.33, which indicates that the market values the company at a significant discount to its book value, suggesting that investors are pricing in the risk associated with the clinical-stage assets and the potential for dilution or failure of the development pipeline. The price-to-sales ratio is 1.15, and the EV/EBITDA is -0.13, suggesting that alternative valuation metrics rely heavily on revenue multiples rather than earnings power, as the negative EV/EBITDA further confirms the lack of profitability in the current business model. The stock has traded between a 52-week high of $9.24 and a 52-week low of $3.91, and depending on the current price, the security is trading within this volatile range, reflecting the uncertainty surrounding the clinical outcomes of its pipeline. The beta value is 0.86, which explains that the stock's price volatility is slightly lower than the broader market, though the high valuation multiples and negative earnings suggest that price movements may be driven more by specific clinical trial data than by general market sentiment.
Growth & Income
The revenue growth year-over-year is N/A, and earnings growth year-over-year is also N/A, indicating that the company does not yet have a historical track record of growth to compare earnings expansion against revenue expansion. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, which explains that the firm reinvests all available resources and earnings back into research and development rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of current profitability and dividend distribution, relying entirely on future clinical successes to generate revenue and shareholder returns.